EPS: As of FY2025 Q3, the actual value is USD 0.57.<h3>Segment Revenue</h3><ul><li>The company operates as a single segment focused on research, discovery, and clinical development of human gene therapy products.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The company reported a net loss of $28.991 million for the three months ended July 31, 2025, compared to $14.148 million for the same period in 2024. For the nine months ended July 31, 2025, the net loss was $79.422 million, compared to $39.843 million in 2024.</li><li>Research and Development Expenses: Increased to $22.575 million for the three months ended July 31, 2025, from $11.549 million in 2024. For the nine months ended July 31, 2025, these expenses were $62.758 million, up from $27.042 million in 2024.</li><li>General and Administrative Expenses: Increased to $7.372 million for the three months ended July 31, 2025, from $5.210 million in 2024. For the nine months ended July 31, 2025, these expenses were $20.926 million, compared to $17.800 million in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended July 31, 2025, net cash used was - $74.277 million, compared to - $28.713 million in 2024.</li><li>Net Cash Used in Investing Activities: For the nine months ended July 31, 2025, net cash used was - $65.638 million, compared to - $0.687 million in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended July 31, 2025, net cash used was - $0.467 million, compared to $205.556 million provided in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to advance the ongoing LEGEND study of detalimogene, including the pivotal cohort of patients with BCG-unresponsive NMIBC, to completion and file a Biologics License Application with the FDA in 2H 2026.</li><li>Non-Core Business: The company is exploring the clinical application of detalimogene to other forms of NMIBC and expanding the cancer indications that can be treated with detalimogene.</li><li>Priority: The company expects to incur significant expenses as it establishes medical affairs, sales, marketing, and distribution infrastructure to support the potential commercial launch of detalimogene.</li></ul>

ENGENE HOLDINGS INC C/WTS 31/10/2028 (TO PUR COM) CL A | 10-Q: FY2025 Q3 EPS: USD 0.57